Marlon Cowart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marlon Cowart has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
A. A. Hancock
Abbott Laboratories
4 shared publicationsArthur A. Hancock
4 shared publicationsJorge D. Brioni
Department of Neuroscience Research, Abbott Laboratories, Abbott Park, IL 60064, United States
4 shared publicationsT. A. Esbenshade
Abbott Laboratories
4 shared publicationsTimothy A. Esbenshade
Department of Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064-6123
4 shared publicationsAndrew O. Stewart
Department of Neuroscience Research, Abbott Laboratories, Abbott Park, Illinois 60064-6123
3 shared publications
Latest Publications
- 5 April 2012
- Published by Elsevier in European Journal of Pharmacology
- Vol. 684 (1-3) , 87-94
Pharmacological characterization of A-960656, a histamine H3 receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain
- 5 April 2012
- Published by Elsevier in European Journal of Pharmacology
- Vol. 684 (1-3) , 87-94
Pharmacological characterization of A-960656, a histamine H3 receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain
- 26 September 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (20) , 6547-6557
Rotationally Constrained 2,4-Diamino-5,6-disubstituted Pyrimidines: A New Class of Histamine H4Receptor Antagonists with Improved Druglikeness and in Vivo Efficacy in Pain and Inflammation Models
A new structural class of histamine H4 receptor antagonists (6−14) was designed based on rotationally restricted 2,4-diaminopyrimidines. Series compounds showed potent and selective in vitro H4 antagonism across multiple species, good CNS penetration, improved PK properties compared to reference H4 antagonists, functional H4 antagonism in cellular and in vivo pharmacological assays, and in vivo anti-inflammatory and antinociceptive efficacy. One compound, 10 (A-943931), combined the best features of the series in a single molecule and is an excellent tool compound to probe H4 pharmacology. It is a potent H4 antagonist in functional assays across species (FLIPR Ca2+ flux, Kb < 5.7 nM), has high (>190×) selectivity for H4, and combines good PK in rats and mice (t1/2 of 2.6 and 1.6 h, oral bioavailability of 37% and 90%) with anti-inflammatory activity (ED50 = 37 μmol/kg, mouse) and efficacy in pain models (thermal hyperalgesia, ED50 = 72 μmol/kg, rat).
- 26 September 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (20) , 6547-6557
Rotationally Constrained 2,4-Diamino-5,6-disubstituted Pyrimidines: A New Class of Histamine H4Receptor Antagonists with Improved Druglikeness and in Vivo Efficacy in Pain and Inflammation Models
A new structural class of histamine H4 receptor antagonists (6−14) was designed based on rotationally restricted 2,4-diaminopyrimidines. Series compounds showed potent and selective in vitro H4 antagonism across multiple species, good CNS penetration, improved PK properties compared to reference H4 antagonists, functional H4 antagonism in cellular and in vivo pharmacological assays, and in vivo anti-inflammatory and antinociceptive efficacy. One compound, 10 (A-943931), combined the best features of the series in a single molecule and is an excellent tool compound to probe H4 pharmacology. It is a potent H4 antagonist in functional assays across species (FLIPR Ca2+ flux, Kb < 5.7 nM), has high (>190×) selectivity for H4, and combines good PK in rats and mice (t1/2 of 2.6 and 1.6 h, oral bioavailability of 37% and 90%) with anti-inflammatory activity (ED50 = 37 μmol/kg, mouse) and efficacy in pain models (thermal hyperalgesia, ED50 = 72 μmol/kg, rat).
- 1 April 2007
- Published by Elsevier in Biochemical Pharmacology
- Vol. 73 (8) , 1243-1255
Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: In vitro properties, drug-likeness, and behavioral activity
- 1 April 2007
- Published by Elsevier in Biochemical Pharmacology
- Vol. 73 (8) , 1243-1255
Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: In vitro properties, drug-likeness, and behavioral activity
- 19 February 2007
- Published by Springer Nature in Inflammation Research
- Vol. 56 (S1) , S47-S48
A new family of histamine H3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series
- 19 February 2007
- Published by Springer Nature in Inflammation Research
- Vol. 56 (S1) , S47-S48
A new family of histamine H3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series
- 1 April 2006
- Published by Springer Nature in Inflammation Research
- Vol. 55 (S1) , S47-S48
Fluorescent benzofuran histamine H3 receptor antagonists with sub-nanomolar potency
- 1 April 2006
- Published by Springer Nature in Inflammation Research
- Vol. 55 (S1) , S47-S48
Fluorescent benzofuran histamine H3 receptor antagonists with sub-nanomolar potency
- 1 April 2005
- Published by Springer Nature in Inflammation Research
- Vol. 54 (S1) , S25-S26
Achievement of behavioral efficacy and improved potency in new heterocyclic analogs of benzofuran H3 antagonists
- 1 April 2005
- Published by Springer Nature in Inflammation Research
- Vol. 54 (S1) , S25-S26
Achievement of behavioral efficacy and improved potency in new heterocyclic analogs of benzofuran H3 antagonists
- 13 December 2004
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (1) , 38-55
4-(2-[2-(2(R)-Methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and Related 2-Aminoethylbenzofuran H3 Receptor Antagonists Potently Enhance Cognition and Attention
H3 receptor antagonists based on a 2-aminoethylbenzofuran skeleton have been discovered, which are potent in vitro at human and rat H3 receptors, with Ki values of 0.1−5.8 nM. Analogues were discovered with potent (0.01−1 mg/kg) cognition and attention enhancing properties in animal models. One compound in particular, 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile (ABT-239), combined potent and selective H3 receptor antagonism and excellent pharmacokinetic and metabolic properties across species, with full efficacy in two behavioral models: a five-trial inhibitory avoidance acquisition model in rat pups at 0.1 mg/kg and a social recognition memory model in adult rats at 0.01 mg/kg. Furthermore, this compound did not stimulate locomotor activity and showed high selectivity for the induction of behavioral efficacy versus central nervous system based side effects. The potency and selectivity of this compound and of analogues from this class support the potential of H3 receptor antagonists for the treatment of cognitive dysfunction.
- 13 December 2004
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (1) , 38-55
4-(2-[2-(2(R)-Methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and Related 2-Aminoethylbenzofuran H3 Receptor Antagonists Potently Enhance Cognition and Attention
H3 receptor antagonists based on a 2-aminoethylbenzofuran skeleton have been discovered, which are potent in vitro at human and rat H3 receptors, with Ki values of 0.1−5.8 nM. Analogues were discovered with potent (0.01−1 mg/kg) cognition and attention enhancing properties in animal models. One compound in particular, 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile (ABT-239), combined potent and selective H3 receptor antagonism and excellent pharmacokinetic and metabolic properties across species, with full efficacy in two behavioral models: a five-trial inhibitory avoidance acquisition model in rat pups at 0.1 mg/kg and a social recognition memory model in adult rats at 0.01 mg/kg. Furthermore, this compound did not stimulate locomotor activity and showed high selectivity for the induction of behavioral efficacy versus central nervous system based side effects. The potency and selectivity of this compound and of analogues from this class support the potential of H3 receptor antagonists for the treatment of cognitive dysfunction.
- 1 November 2004
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 4 (9) , 979-992
Medicinal Chemistry and Biological Properties of Non-Imidazole Histamine H3 Antagonists
The H3 receptor is prominently expressed in neuronal tissues, and H3 antagonists have been proposed as drugs with benefits in disorders of cognition, attention, pain, allergic rhinitis, and obesity. The structure-activity relationships (SAR) of various classes of non-imidazole H3 antagonists are reviewed, along with highlights of functional efficacy in tissue-based and animal disease models.
- 1 November 2004
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 4 (9) , 979-992
Medicinal Chemistry and Biological Properties of Non-Imidazole Histamine H3 Antagonists
The H3 receptor is prominently expressed in neuronal tissues, and H3 antagonists have been proposed as drugs with benefits in disorders of cognition, attention, pain, allergic rhinitis, and obesity. The structure-activity relationships (SAR) of various classes of non-imidazole H3 antagonists are reviewed, along with highlights of functional efficacy in tissue-based and animal disease models.
- 10 June 2004
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (15) , 3853-3864
Discovery of 2-(4-Pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a Dopaminergic Agent with a Novel Mode of Action for the Potential Treatment of Erectile Dysfunction
A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead agent 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (1, ABT-724) was discovered by optimization of a series of benzimidazole arylpiperazines. This highly selective D4 agonist was found to be very potent and efficacious in vivo, eliciting penile erections in rats at a dose of 0.03 μmol/kg, with a positive response rate of 77% erectile incidence. Even at high doses, it was devoid of side effects in animal models of central nervous system behaviors, emesis, or nausea. The structure−activity relationship of the parent benzimidazole series leading to 1 is described, with the detailed in vitro and in vivo profiles described. Distinctive structural features were discovered that are associated with D4 selective agonism in this series of analogues.
- 10 June 2004
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (15) , 3853-3864
Discovery of 2-(4-Pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a Dopaminergic Agent with a Novel Mode of Action for the Potential Treatment of Erectile Dysfunction
A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead agent 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (1, ABT-724) was discovered by optimization of a series of benzimidazole arylpiperazines. This highly selective D4 agonist was found to be very potent and efficacious in vivo, eliciting penile erections in rats at a dose of 0.03 μmol/kg, with a positive response rate of 77% erectile incidence. Even at high doses, it was devoid of side effects in animal models of central nervous system behaviors, emesis, or nausea. The structure−activity relationship of the parent benzimidazole series leading to 1 is described, with the detailed in vitro and in vivo profiles described. Distinctive structural features were discovered that are associated with D4 selective agonism in this series of analogues.
- 1 March 2004
- Published by Springer Nature in Inflammation Research
- Vol. 53 (1) , S69-S70
The medicinal chemistry of novel H 3 antagonists
- 1 March 2004
- Published by Springer Nature in Inflammation Research
- Vol. 53 (1) , S69-S70
The medicinal chemistry of novel H 3 antagonists